Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipase A2 group IVB (PLA2G4B)
- Target
- PLA2G4B
- Molecular classification
- Enzyme, Cytosolic phospholipase A2 family member
01
Overview
Phospholipase A2 group IVB (PLA2G4B) is a cytosolic enzyme belonging to the phospholipase A2 superfamily, primarily responsible for hydrolyzing the sn-2 acyl bond of phospholipids in cellular membranes and releasing free fatty acids and lysophospholipids. Unlike group IVA (cPLA2-alpha), PLA2G4B is less studied, with possible association with intracellular compartments such as mitochondria and early endosomes. Biological roles include modulation of lipid signaling pathways, which can influence inflammation and cell survival. Gene fusions (JMJD7–PLA2G4B) have been linked to oncogenic AKT pathway activation. Although considered a potential therapeutic target due to its enzymatic activity, drug development is predominantly focused on other PLA2 family members, and specific clinical applications for PLA2G4B remain undeveloped.
- Other names
- Cytosolic phospholipase A2 betacPLA2-betaHsT16992Lysophospholipase A1 group IVBPhospholipase A2, group IVB (cytosolic)cPLA2-βGm1013A030011C02Rik
02
Mechanism of action
Not directly drug-targeted; general PLA2 inhibitors block hydrolysis of phospholipids, reduce production of eicosanoids and lysophospholipids
03
Biological functions
Hydrolyzes the sn-2 bond of membrane phospholipidsReleases lysophospholipids and fatty acidsMay be associated with mitochondria and early endosomes
04
Disease associations
Cancer (oncogenic fusion JMJD7‑PLA2G4B can modulate AKT signaling)Inflammation (through release of lipid mediators)Other (potential implications in metabolic and signaling disorders, not fully characterized)
05
Safety considerations
General concerns for PLA2 inhibition include disruption of lipid mediator signaling, potential GI and immunological effects as seen with group IVA inhibition; PLA2G4B inhibition-specific risks not characterized
06
Interacting drugs
No specific drugs for PLA2G4B identified; most phospholipase A2 inhibitors target the group IVA subtype or other group members
07
Biomarkers
No established or validated biomarkers specific for PLA2G4B; research mainly in gene expression profiling or fusion status in oncology and in functional genomics screens
Beyond the preview
Go deeper on Phospholipase A2 group IVB (PLA2G4B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phospholipase A2 group IVB (PLA2G4B).